Picture loading failed.

Anti-CSF2 therapeutic antibody (Pre-made Lenzilumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Lenzilumab (INN; development code KB003)[1] is a humanized monoclonal antibody (class IgG1 kappa)[2] that targets colony stimulating factor 2 (CSF2)/granulocyte-macrophage colony stimulating factor (GM-CSF).

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-303-1mg 1mg 3090
GMP-Bios-ab-303-10mg 10mg 21890
GMP-Bios-ab-303-100mg 100mg 148000
GMP-Bios-ab-303-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-CSF2 therapeutic antibody (Pre-made Lenzilumab biosimilar,Whole mAb)
INN Name Lenzilumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2014
Year Recommended2015
CompaniesHumanigen;KaloBios Pharmaceuticals
Conditions Approvedna
Conditions ActiveCOVID-19;Cytokine release syndrome;B-cell lymphoma;Drug hypersensitivity;Precursor cell lymphoblastic leukaemia-lymphoma;Graft-versus-host disease
Conditions DiscontinuedAsthma;Rheumatoid arthritis;Chronic myelomonocytic leukaemia;Solid tumours
Development TechHumaneering Technology